Summary Inhibition of the multiplication of My cobacterium leprae in the fo otpads of nude mice by the oral administration of sparfloxacin, a new quinolone, and 3 ' -hydroxy-5 ' -(4-isobutyl-l -piperazinyl)benzoxazinorifamydn (KRM-I648), selected from a series of newly synthesized benzoxazinorifamy cins, was studied. When the 2 drugs were administered alternately at intervals of 3 or 4 days, (i.e., each drug was administered once weekly), or simultaneously once weekly, between 3 and 5 months after inoculation of nude mice with M. leprae, lOmg sparfloxacin and 0'6 mg KRM-1648 per kg bodyweight were sufficient to prevent multiplication of the organisms. Only partial inhibition of multiplication was achieved by alternate administration of 5 mg sparfloxacin and O' 3 mg KRM -1648 per kg, as was the case for 20 mg sparfloxacin per kg or 1 mg KRM-1648, each drug administered alone once weekly. The addition to these 2 drugs of dapsone, administered in the diet in a concentration of 0·00 1 g per 100 g, enhanced their effect.
The potential usefulness of multidrug regimens induding these compounds is considered.
We have previously reported that a new rifamycin derivative, 3 ' -hydroxy-S ' -(4-isobutyl-1-piperazinyl)benzoxazinorifamycin (KRM-1648) (see Figure 1 for structure) entirely prevented the multiplication of M. /eprae in the fo otpads of congenitally athymic nu/nu (nude) mice, when the drug was administered twice weekly per os in dosages of I or 3 mg per kg bodyweight between 3 and S months after the animals had been inoculated. l We have also reported that administration of sparfloxacin (SPFX) in dosages of 10, 20 or 30 mg per kg by the same schedule partially inhibited the multiplication of the organisms. 2 In this paper, we report the results of several experiments §Present address: Aoba-cho 2-29-11, Higashimurayama, Tokyo 189, Japan.
0305-7518/95/066039 +09 $01.00 © Lepra 40 M. Gidoh et al. in M. leprae-infected nude mice, in which these 2 drugs were administered alternately or simultaneously at weekly intervals.
Materials and methods
KRM-1648 was supplied by the Biochemical Research Laboratories, Kaneka Corpora tion, Ltd., and SPFX by the Bioscience Research Laboratories, Dainippon Pharmaceu tical Co., Ltd. Emulsified suspensions of KRM-1 648 and SPFX were prepared and preserved as described previously. 1 , 2 These 2 drugs were administered through mouse catheters alternately at intervals of 3 or 4 days (each drug was administered once weekly) in experiments 1 and 2, whereas they were administered simultaneously at intervals of 1 week in experiment 3. Dapsone, purchased fr om Wako Pure Chemicals Co., Ltd., Tokyo, and fo rmulated into heat-stable pellets by Funabashi Nojyo Co., Ltd., Chiba, Japan, was administered incorporated in their diet in a concentration of 0·001 g per 100 g in experiment 4.
Female BALB/c nu/nu mice, aged 5 weeks, were purchased fr om Clea Japan Inc., Tokyo. The mice were bred and grouped as described earlier. 1 , 2 M. leprae of the Thai 53 strain, 1 , 2 , 4 which had been maintained in nude mice through 10 or 11 passages, were employed. Inocula were prepared and the mice infected as described in .our earlier reports, I , 2 except that 10 7 organism were inoculated into each hind fo otpad. Acid-fast bacilli (AFB) were harvested individually (2 hind fo otpads were pooled), and enumerated by the method of Shepard & McRae. 5 Each time 20 microscopic fields were counted for each of 2 circular smear spots of l-cm diameter with fields of AFBs comparatively uniformly distributing, as a portion of supernatant fr om emulsified 2 hind fo otpads pooled fr om each animal, and the average count of AFB and the standard deviation (SD) were calculated for 2 or 3 animals.
ALTERNATE ADMINISTRATION OF KRM-1648 AND SPFX
In experiment 1, KRM-1648 was administered per os in a dosage of 1 mg per kg bodyweight every Friday, and SPFX was administered per os in a dosage of 10 or 20 mg per kg every Monday, from the beginning of the 3rd month until the end of the 5th month after the nude mice had been inoculated with 10 7 M. /eprae into each hind fo otpad. As shown in Figure 2 , administration of KRM-1648 alone or of SPFX alone in Figure 2 . Inhibition of multiplication of M. leprae inoculated into nude mouse footpads by alternate treatment with KRM-1 648 and sparfloxacin (SPFX) at intervals of 3 or 4 days. Groups of 10 nude mice were infected with M. leprae, strain Thai 53 by 1 x 10 7 bacilli into each of both hind footpads and then treated with oral administration of KRM-1 648 and SPFX, alternately at intervals of 3 or 4 days (each drug was administered once weekly), between 3 and 5 months after inoculation. Otherwise, animals were orally treated with KRM-1648 or with SPFX, once weekly. We took 4 or 6 fo otpads of 2 or 3 mice at the indicated months after inoculation and AFBs in the footpads were counted up. Table 1 . Number of AFBs detected at 9 and II months after inoculation, in the 4 footpads of 2 mice, respectively, belonging to the 2 groups shown in Figure 2 Group AFBjFP Control 1·\2 x 10 9 0·89 X 10 9
KRM Imgjkg+ 1·89 x 10 6 SPFX 10mgjkg 1·14 the higher dosage only partially inhibited multiplication of the M. leprae. On the other hand, alternate administration of these 2 drugs entirely prevented multiplication of the organisms, even when SPFX was administered in the lower dosage. As for 2 groups in Figure 2 in which detected AFBs were always below the number of M. leprae inoculated into each fo ot pad, the results are demonstrated by number of AFBs at 9 and 11 months after inoculation, as shown in Table 1 . In experiment 2, the efficacy was tested of the drugs administered in smaller dosages by the same schedule. As shown in Figure 3 , weekly administration of SPFX in the dosage of 10 mg per kg only partially inhibited the multiplication of the M. leprae, as may also have been the case for KRM-1648 administered in a weekly dosage of O'6 mg per kg. Similarly, the alternate administration of 5 mg SPFX and 0·3 mg KRM-1 648 per kg was only partially inhibitory, whereas alternate administration of lOmg SPFX and 0·6 mg KRM -1648 entirely prevented the multiplication of the organisms.
SIMULTANEOUS ADMINISTRATION OF KRM-1648 AND SPFX
In experiment 3, the 2 drugs were administered simultaneously on 12 occasions 1 week apart. As shown in Figure 4 , the combination of lOmg SPFX per kg with KRM-1648, the latter drug administered in a dosage of 0·6 or 1·0 mg per kg, entirely prevented multiplication of the organisms, as had been the case when the 2 drugs were administered alternately.
COMBINATION OF KRM-1 648 AND SPFX WITH DAPSONE
In the final experiment, 2 groups of mice were administered dapsone in their diet at a concentration of 0·00 1 g per 100 g for 3 months, fr om the beginning of the 3rd month to the end of the 5th month after inoculation. In addition, 0·6 mg KRM-1648 and lOmg SPFX were administered simultaneously once weekly to I of the groups from the start till the end of dapsone administration. Administration of these 3 drugs alone only partially inhibited the multiplication of the M. leprae, whereas the simultaneous administration of KRM-1648 and SPFX entirely prevented their multiplication. The addition of dapsone appears to have enhanced the efficacy of the 2-drug combination. Table 2 . Number of AFBs detected at 9 and 11 months after inoculation, in the 4 footpads of 2 mice, respectively, belonging to the 3 groups shown in Figure 5 Number of acid-fast bacilli detected The results of 3 groups shown in Figure 5 , in which multiplication of M. /eprae was suppressed to a level comparable to or below the number of the organisms inoculated into each fo otpad, are demonstrated by the detected number of AFB in Table 2 .
Discussion
The inhibitory effect on multiplication of M. leprae by sparfloxacin and KRM-1 648 administered alternately at intervals of 3 or 4 days or simultaneously at intervals of 1 week were determined using an M. leprae infection model in nude mouse fo otpads.
Findings demonstrated that lOmg of sparfloxacin and 0'6mg of KRM-1648 per kg bodyweight were sufficient to prevent entirely the multiplication of M. leprae in mouse fo otpads in both the dosing methods. Nevertheless, when the 2 agents were combined, administration of 5 mg of the fo rmer and O' 3 mg of the latter per kg of bodyweight at 1-week intervals proved to be insufficient. Review of the findings of our experiments suggests that the alternative administration of 20 mg of sparfloxacin and 1 mg of KRM-1648 per kg of bodyweight at intervals of 3 or 4 days (1st experiment) and the simultaneous administration of lOmg of sparfloxacin with 0'6mg of KRM-1 648 per kg of body weight combined with dapsone (4th experiment) seem to be the 2 most potent regimens. An adverse effect of rifamycin analogues is the toxicity to hepatic enzymes 7 and blood cells at high dosages. 8 Repeated use of high-dose rifabutin or rifampicin induces predominancy of extrahepatic metabolism, which appears to reduce AUC. 9 For this reason, lower dosage and frequency of administration are best for rifamycin analogues. KRM-1 648 is useful not only because it can be administered in low doses but also because it may achieve economical inhibition of the multiplication of M. leprae. tuberculosis in vitro has also been reported. 1 3 These findings remind us of the importance of completely eradicating M. leprae as rapidly as possible with strong MDT.
In the 4th experiment, dapsone was tested in combination with KRM-1648 and sparfloxacin. Pronounced inhibition of multiplication as evidenced by reduction even in the number of nonsolid bacilli was observed. However, if the amount of dapsone contained in the 0·001 %-DDS diet is converted to the amount in the diet of an adult weighing 60 kg, it corresponds to approximately 72-150 mg daily. Although the tissue concentrations of KRM-1648 are higher in the spleen than in the liver, 1 while those of sparfloxacin 14 and dapsone are the opposite, a devised administration of dapsone to decrease the metabolic load on the host due to this multidrug regimen can be expected fo r clinical use, particularly because both KRM-1 648 and sparfloxacin are long-acting substances, but also because dapsone exhibits slow clearance.
Recently, Franzblau et al. (personal communication) examined the clinical effect of sparfloxacin on 9 lepromatous cases using assay of PGL-l antigen, determination of killing of leprosy bacilli with the mouse fo otpad method, and a radiorespirometry. Daily treatment with 200 mg sparfloxacin for 12 weeks was found to be sufficiently effective. This dosage of sparfloxacin corresponds at most to only 20-40% of those used for nude mice in the present study.
Given these findings, studies on rapid and complete eradication of M. leprae with a minimal number of combined administration of KRM-1648 and sparfloxacin with or without dapsone will be continued using the M. leprae infection model in nude mice as described here.
